Our company name, Centricity Vision, Inc., reflects our company’s expertise, expanded product offerings in cataract surgery, and continued commitment to customers and patients.
As a global ophthalmic technology company, we take pride in delivering innovative solutions that help surgeons across the world achieve surgical and clinical excellence.
Currently, we’re focusing on our unprecedented ZEPTO® Precision Cataract Surgery platform as it continues to advance the safety and precision of cataract surgery outcomes in a convenient, cost-effective, and disposable format. The ZEPTO® platform provides precise, repeatable, circular, and visual axis–oriented capsulotomies that facilitate 360° overlap of the IOL optic.1 ZEPTO® automates the anterior capsulotomy, using a proprietary combination of calibrated suction and a four-millisecond, multi-pulse energy algorithm to produce highly accurate capsulotomies simplifying the surgeon’s ability to align on the visual axis of the eye during surgery using patient fixation.1
Moving forward, we’ll leverage this microsurgical technology to create a suite of products for ophthalmic capsular management. Our relentless commitment to developing solutions of the highest quality and technological sophistication is uncompromising—as is our dedication to assisting physicians in delivering the best care to patients.
Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, today announced two product innovations under development, the ZEPTOLINK platform and ZEPTO 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, Pharm. D, to lead research and development.
Our CEO, Rob Thornhill, gave an exclusive interview to The Ophthalmologist before this year’s AAO meeting in New Orleans. See what Rob has to say about his vision for the company and his excitement at the difference being made by ZEPTO capsulotomy technology.
Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, announced Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the ZEPTO Platform.
Our next generation of ZEPTO® is here with over 16 newly enhanced features! Experience the new handpiece and new power console – now optimized with improved usability, enhanced safety and for strong capsulotomies with a 360° IOL overlap.
Centricity Vision is proud to be featured in the July edition of Ophthalmology Management with the next generation of ZEPTO® Spotlight Technology & Technique article. Click to open the PDF of the article.
Centricity Vision, Inc., a global ophthalmic technology company dedicated to delivering solutions that help surgeons achieve surgical and clinical excellence, today announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mazzo is one of the ophthalmic industry’s best known and most well respected business leaders with over 40 years of proven experience. “I am excited to join Centricity Vision’s Board of Directors and look forward to working with this exceptional team to increase global access to the ZEPTO Platform,” said Mazzo.
Dr. Ehsan Sadri and Rob Thornhill discuss the benefits of the Zepto Precision Cataract Surgery device in delivering automated, precise, circular, and centered capsulotomies – how their business model evolved during COVID-19 and the future direction for the company.
Centricity Vision, Inc., formerly known as Mynosys Cellular Devices, Inc., a global ophthalmic technology company dedicated to delivering products that help surgeons optimize outcomes in refractive surgery, today announced a new executive leadership team, along with a new company name.
REFERENCE 1: Thompson V. Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis. J Cataract Refract Surg. 2018;44(5):528-533.
President & CEO
Rob is a start-up and large company medical device executive with equity fund-raising, business development, clinical study, and successful exit transactional experience. He has deep commercial operational experience with teams of up to 200 employees. Prior to joining Centricity Vision, Inc., Rob served as the founding CEO of Tear Film Innovations, Inc.,–manufacturer of the iLux treatment device for dry eye disease, which he led from seed stage through a Series B financing and then successfully sold to Alcon in 2018.
Chief Financial Officer
Louis has more than 26 years of experience as a senior financial executive with early-stage medical device companies. He was instrumental in raising in excess of $200 million in venture equity and debt as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value. Prior to joining Centricity Vision, Louis was CFO of ReVision Optics, Inc., a corneal inlay company. Prior experience included serving as CFO and participating in the sale of 3F Therapeutics, Inc., a tissue heart-valve company, acquired by ATS Medical, Inc., EndiCOR Medical, Inc., a coronary catheter company, acquired by Ev3, Inc., and SenDx Medical, Inc., a critical care diagnostic company, acquired by Radiometer. Prior to joining SenDx, Louis served as a Senior Audit Manager with Ernst & Young.
Chief Commercial Officer
Todd is a proven medical device and biotechnology commercial leader with an achievement record of more than 27 years. He demonstrated success in driving multimillion-dollar revenue growth while providing strategic marketing and sales leadership in highly competitive markets. Todd has commercial expertise in start-up, turnaround, and mature companies with significant business development and capital fundraising exposure. Prior to joining Centricity Vision, Todd led all commercial launch efforts for the XEN® Surgical Treatment System at Allergan. Todd graduated from Temple University with a Master’s Degree in International Business and holds a B.S. in Marketing from of Pittsburgh.
Vice President, Research and Development
Mark brings to Centricity Vision more than 40 years of experience in leading and managing the research development of surgical products in ophthalmology with medical device companies, such as CooperVision, Alcon, Chiron Vision, Allergan, Advanced Medical Optics, Abbott, and Johnson & Johnson. Mark has a broad range of competencies including mechanical design, machining, plastics forming, electronics and software, with a specific focus on ultrasonic systems and advanced laser technologies. His deep experience in product innovation, commercialization, and product lifecycle management spans from advanced research and physician liaising to technology transfers in merger and acquisitions by larger corporations. Mark has been named inventor on numerous patents with proven IP portfolio management and protection.
Vice President, RA and Quality Assurance
Nealen has more than 20 years of experience with start-ups to large medical device companies supporting regulatory affairs, quality assurance, and quality engineering. He gained FDA clearance and international registration of various types of devices ranging from single-use disposables to electro mechanical devices. Nealen established and maintained quality management systems that have been successfully audited and inspected by the FDA, notified bodies, and international entities. He was also involved with a handful of acquisitions, with the latest being the acquisition of Tear Film Innovation, Inc. by Alcon.